Abstract
Gene therapy vectors discussed here are oncoretrovirus and lentivirus based. Both types of vectors are integrating vectors; they are permanently and semi-randomly inserting their genetic information into the nucleus of the cell to be gene modified. The machinery of the original virus is being used to deliver the gene of interest; however, the virus particle has been rendered completely replication incompetent by removing all viral genes from the vector particle. Anti-HIV genes, which are packaged into these vector particles for delivery into the target cells, can be single genes or a combination of multiple genes, with their active anti-HIV component being RNA or protein based. Safety features have been engineered into latest generation lentiviral vectors, and efficient vector production methods based on transient plasmid transfection methods have been developed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Woffendin C et al (1994) Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells. Proc Natl Acad Sci U S A 91(24):11581–11585
Kohn DB et al (1999) A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 94(1):368–371
Podsakoff GM et al (2005) Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol Ther 12(1):77–86
Michienzi A et al (2002) A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A 99(22):14047–14052
Anderson J, Akkina R (2005) TRIM5alpharh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages. Mol Ther 12(4):687–696
DiGiusto DL et al (2010) RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2(36):36ra43
Vigna E, Naldini L (2000) Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2(5):308–316
Deichmann A et al (2011) Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. Mol Ther 19(11):2031–2039
Mantovani J et al (2009) Diverse genomic integration of a lentiviral vector developed for the treatment of Wiskott-Aldrich syndrome. J Gene Med 11(8):645–654
Naldini L et al (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272(5259):263–267
Zufferey R et al (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15(9):871–875
Koya RC et al (2002) Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses. Leukemia 16(9):1645–1654
Whitwam T, Peretz M, Poeschla E (2001) Identification of a central DNA flap in feline immunodeficiency virus. J Virol 75(19):9407–9414
Higashimoto T et al (2007) The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors. Gene Ther 14(17):1298–1304
Di Matteo M et al (2012) Recent developments in transposon-mediated gene therapy. Expert Opin Biol Ther 12(7):841–858
Schroers R et al (2002) Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection. Gene Ther 9(13):889–897
Zhang MY et al (2010) Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. MAbs 2(3):266–274
Holt N et al (2010) Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28(8):839–847
Smyth RP, Davenport MP, Mak J (2012) The origin of genetic diversity in HIV-1. Virus Res 169(2):415–429
Zhou J, Rossi JJ (2011) Aptamer-targeted RNAi for HIV-1 therapy. Methods Mol Biol 721:355–371
Burnett JC, Rossi JJ (2012) RNA-based therapeutics: current progress and future prospects. Chem Biol 19(1):60–71
Zhou J, Rossi JJ (2011) Progress in RNAi-based antiviral therapeutics. Methods Mol Biol 721:67–75
Mitsuyasu RT et al (2009) Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 15(3):285–292
Humeau LM et al (2004) Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther 9(6):902–913
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2014 Gerhard Bauer and Joseph S. Anderson
About this chapter
Cite this chapter
Bauer, G., Anderson, J.S. (2014). Gene Therapy Vectors. In: Gene Therapy for HIV. SpringerBriefs in Biochemistry and Molecular Biology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0434-1_4
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0434-1_4
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0433-4
Online ISBN: 978-1-4939-0434-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)